$KEQU

Ranade Mandar sold (to issuer) $65K of KEQU

Ranade Mandar (SVP, IT & Engineering) sold (to issuer) 1,800 shares of KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) at $36.25 on 2026-06-30.

Original reporting
SEC EDGAR · Ranade Mandar
Published Jul 2, 2026, 3:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 2, 2026, 3:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$KEQU
Neutral
high confidence
Mentioned
$KEQU
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KEQUNeutralLow
01

Why it matters

The newest fact is the reported sale of 1,800 shares at $36.25 on 2026-06-30; absent other company news, it mainly updates insider activity records.

02

Market read

Traders may note insider selling activity, but the filing provides no new operational/financial catalyst.

03

What to watch

Check whether there are multiple insider transactions around the same period, and whether the issuer’s buyback/repurchase program mechanics explain “sale to issuer” activity.

Relevance 3/10Novelty 5/10Timing: filed 2026-07-02 (after-hours/late day) for 2026-06-30 sale

Background

The article is an SEC Form 4 insider transaction disclosure for KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU).

Company-level read

Ticker impact

$KEQUNeutralHigh confidence
Context

Ranade Mandar (SVP, IT & Engineering) sold 1,800 KEQU shares to the issuer at $36.25 on 2026-06-30, per Form 4.

Expected impact

Low near-term impact; any effect is likely noise unless repeated at unusual frequency or tied to new disclosures.

Evidence & confidence

This is a Form 4 insider transaction with no 10b5-1 plan and no accompanying fundamental catalyst in the filing text; such sales are typically not directionally informative by themselves.

Market effects

No sector-level read-across; this is company-specific insider liquidity disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is to the issuer (often buyback/participation mechanics) and the filing lacks a 10b5-1 plan, the transaction may reflect administrative/plan mechanics rather than bearish conviction.

Key entities

  • KEWAUNEE SCIENTIFIC CORP /DE/

    Subject of the Form 4 insider transaction; ticker KEQU.

  • Ranade Mandar

    SVP, IT & Engineering; reported sale to issuer of 1,800 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$KEQUMed

Kewanee Scientific To Buy Nycom

Kewaunee Scientific (KEQU) agreed to acquire Nycom, the largest U.S. laboratory dealer. The deal aims to combine Nycom's expertise with Kewaunee's manufacturing for integrated solutions. KEQU shares traded down 1.19% at $32.61.

$KEQUMed

Kewaunee Scientific Announces Agreement to Acquire Nycom, Inc.

Kewaunee Scientific (KEQU) agreed to acquire Nycom, a major lab dealer, for $55M, with $20M in notes, $5M in stock, and the rest in cash. The deal aims to combine Nycom's project expertise with Kewaunee's manufacturing, enhancing lab solutions. Nycom's leadership will join Kewaunee's board and management. The transaction is expected to close in Q4 2027, pending approvals.

$KEQUMed

Kewaunee Scientific Reports Results for First Quarter of Fiscal Year 2027

KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Kewaunee Scientific Reports Results for First Quarter of Fiscal Year 2027 Exchange: NASDAQ (KEQU) Contact: Donald T. Gardner III 704/871-3274 STATESVILLE, N.C. September 9, 2026 – PRNewswire / Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its first qu

$KEQUMed

Kewaunee Scientific Reports Results for Fiscal Year and Fourth Quarter

KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 prfy26q4earningsrelease.htm EX-99.1 Document Kewaunee Scientific Reports Results for Fiscal Year and Fourth Quarter Exchange: NASDAQ (KEQU) Contact: Donald T. Gardner III 704/871-3274 STATESVILLE, N.C. June 23, 2026 – PRNewswire / Kewaunee Scientific Corporation (NASDAQ